PubMed · PMID 23463522
Antinociceptive effects of H₃ (R-methylhistamine) and GABA(B) (baclofen)-receptor ligands in an orofacial model of pain in rats.
PMID 23463522Journal Neurotoxicity researchYear 2013Authors 5DOI 10.1007/s12640-013-9385-4
Abstract
The present study explored the antinociceptive effects of H₃ (R-methylhistamine) and GABA(B) (baclofen) receptor ligands in an orofacial model of pain in rats. Orofacial pain was induced by subcutaneous injection of formalin (50 μl, 5 %) in the upper lip region, and the number of jumps and time spent face rubbing was recorded for 40 min. Formalin produced a marked biphasic pain response; first phase, 0-10 min (jumps), and second phase, 15-40 min, (rubbing).
Baclofen (50 μg) injected into the rat wiskerpad 5 min before formalin administration suppressed both phases of pain whereas R-alpha-methylhistamine (12.5 μg) abolished the first phase only. Brains were taken immediately after behavioral testing was completed. HPLC/ED analysis showed that 5-hydroxytryptamine (5-HT) turnover was increased in hippocampus, thalamus, and brain stem of all formalin groups, excepting the baclofen group in which the balance of 5-HT metabolism was restored to control values.
These findings demonstrate that GABA(B) receptors represent peripheral targets for analgesia. Consequently, locally administered baclofen may be a useful approach in treating inflammatory trigeminal pain.
Record details
| PMID | 23463522 |
|---|---|
| DOI | 10.1007/s12640-013-9385-4 |
| Journal | Neurotoxicity research |
| Year | 2013 |
| Authors | Przemysław Nowak; Magdalena Kowalińska-Kania; Damian Nowak; Richard M Kostrzewa; Jolanta Malinowska-Borowska |
| MeSH | Animals; Baclofen; Disease Models, Animal; Facial Pain; Female; GABA-B Receptor Agonists; Histamine Agonists; Injections, Subcutaneous; Ligands; Male; Methylhistamines; Pain Measurement; Rats; Rats, Wistar |
Source record
Open the PubMed record. This page reproduces the abstract and citation fields held in the local baseline; it does not rehost the article.